Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Ldl Amp'

Ldl Amp published presentations and documents on DocSlides.

Abnormalities of LDL metabolism
Abnormalities of LDL metabolism
by briana-ranney
Physiology, pathophysiology and treatments. Under...
Is lower better? LDL targets and beyond.
Is lower better? LDL targets and beyond.
by trish-goza
Implications of the relationship between risk fac...
Looking to FOURIER: What do the trials tell us about LDL lowering and cardiovascular events?
Looking to FOURIER: What do the trials tell us about LDL lowering and cardiovascular events?
by min-jolicoeur
NICE –CG 181 Continuum of CVD Risk and its trea...
Is lower better? LDL targets and beyond.
Is lower better? LDL targets and beyond.
by olivia-moreira
Implications of the relationship between risk fac...
LDL Apheresis in Drug Resistant Nephrotic Syndrome
LDL Apheresis in Drug Resistant Nephrotic Syndrome
by obrien
Rodney D Gilbert. Patient JM. 14 year old girl, pr...
LDL is causal of atherosclerosis
LDL is causal of atherosclerosis
by morgan
Evidence from . meta-analyses of . Mendelian. . r...
LDL-CHOLESTEROL Presented By
LDL-CHOLESTEROL Presented By
by williams
Assist.Lecturer. Aseel. . Ghassan. . Daoud. M.Sc...
PCSK9 Inhibition: LDL Lowering
PCSK9 Inhibition: LDL Lowering
by SweetiePie
PCSK9 inhibitors. New option for dyslipidemia. Ali...
Lifestyle Tips to Lower Your LDL Cholesterol
Lifestyle Tips to Lower Your LDL Cholesterol
by dandy
Advice f rom the National Lipid Association Clini...
Residual risk: Is LDL target enough?
Residual risk: Is LDL target enough?
by candy
An interpretation of the continuous relationship b...
New Insights in
New Insights in
by yoshiko-marsland
the Understanding . of . Cholesterol Metabolism:....
Cholesterol and C.V.D.
Cholesterol and C.V.D.
by sherrill-nordquist
Learning outcome. Most cholesterol is synthesised...
Genetic Variants of Proprotein Convertase Subtilisin/Kexin
Genetic Variants of Proprotein Convertase Subtilisin/Kexin
by mitsue-stanley
Type 9 (PCSK9). Implications for Low-Density Lipo...
DIABETES AND LIPID
DIABETES AND LIPID
by yoshiko-marsland
S-KHALILZADEH. Lipids are hydrophobic molecules t...
The State of
The State of
by olivia-moreira
Dyslipidemia. . Treatment. USA-145-101385. © . ...
Health Guide
Health Guide
by min-jolicoeur
By: Rebekah O’Bryan, Naomi Belcher, and Miranda...
Novel therapies for the prevention of atherosclerotic vascu
Novel therapies for the prevention of atherosclerotic vascu
by debby-jeon
Prof. . John . Kastelein. Academic Medical Centre...
Advancing the Understanding
Advancing the Understanding
by briana-ranney
of Cholesterol Metabolism:. The Role of . Proprot...
Familial
Familial
by sherrill-nordquist
Hypercholesterolaemia. . N. ew local pathways. D...
Familial Hypercholesterolemia
Familial Hypercholesterolemia
by faustina-dinatale
KEY POINTS . FH is an autosomal dominant genetic...
Protecting the heart and the kidney:
Protecting the heart and the kidney:
by marina-yarberry
Implications from the SHARP trial. Dr. Christina ...
0 Circulation and Gas Exchange
0 Circulation and Gas Exchange
by tatyana-admore
The fluid that moves around in the circulatory sy...
KA 7d
KA 7d
by olivia-moreira
: Learning Outcomes. State where cholesterol is s...
Familial Hypercholesterolemia
Familial Hypercholesterolemia
by pasty-toler
Developed by . Ms. . Shawna . Morrison, Dr. Judit...
Lipid Metabolism
Lipid Metabolism
by kittie-lecroy
Chapter 29, . Stryer. Short Course. Lipid anabol...
Understanding Blood Lipids
Understanding Blood Lipids
by myesha-ticknor
and Their Relationship to Health. Mark Pettus MD...
Cholesterol Treatment Trialists’ (CTT) Collaboration
Cholesterol Treatment Trialists’ (CTT) Collaboration
by briana-ranney
Slide deck. CTT Collaboration: Background*. Histo...
협심증 ( 狹心症 )
협심증 ( 狹心症 )
by lois-ondreau
Kyung Woo Park, MD, PhD, MBA . Seoul National Uni...
Triglycerides and Risk for Atherothrombosis
Triglycerides and Risk for Atherothrombosis
by briana-ranney
Thomas Dayspring, MD, FACP. Clinical Assistant Pr...
Risk factors in heart disease
Risk factors in heart disease
by faustina-dinatale
Optimizing . patient care. William Cromwell, MD, ...
Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in
Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in
by pamella-moone
Hyperlipidemic. Subjects: A 52 Week Phase 3 Dou...
American Association of Clinical Endocrinologists and American College of Endocrinology
American Association of Clinical Endocrinologists and American College of Endocrinology
by natalia-silvester
Guidelines for Management of Dyslipidemia . and P...
Cholesterol-Lowering Drugs
Cholesterol-Lowering Drugs
by cheryl-pisano
Victor Nadler. Objectives. By the end of this cla...
The Importance of Potential
The Importance of Potential
by pamella-moone
Statin. in High Risk Patient. Masrul Syafri. Bag...
Management of Common Comorbidities in Diabetes
Management of Common Comorbidities in Diabetes
by celsa-spraggs
1. Obesity. Management of Common Comorbidities in...
Fat Nutrition 2102 https://www.youtube.com/watch?v=yWDgf7w6Zw0
Fat Nutrition 2102 https://www.youtube.com/watch?v=yWDgf7w6Zw0
by kittie-lecroy
http://video.about.com/lowfatcooking/Overview-of-...
New developments in lipid management
New developments in lipid management
by pasty-toler
CGR 0800 h 11 May 2015. Rob Hegele MD FRCPC FACP....
Trial Design Evolocumab SC
Trial Design Evolocumab SC
by danika-pritchard
140 mg Q2W or 420 mg QM. Placebo SC. Q2W or QM. L...
LSU Journal Club Efficacy and Safety of
LSU Journal Club Efficacy and Safety of
by trish-goza
Evolocumab. in. Reducing Lipids and Cardiovascul...
PCSK-9 Inhibitors Paul J
PCSK-9 Inhibitors Paul J
by tatyana-admore
PCSK-9 Inhibitors Paul J Kovack , DO, FACC, FACO...